The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Targeted therapy can lose control of a cancer for two broad reasons: some resistant cancer cells were present before treatment, or surviving cells changed while treatment was underway. A drug’s molecular target may change, disappear, or become harder for the drug to affect; alternatively, the cancer may activate another growth or survival pathway. A single tumor can use several resistance mechanisms at once.
Resistance is not something a patient can diagnose from symptoms alone. Oncologists establish whether the cancer is progressing with examinations, blood work, imaging and, when useful, updated biomarker testing. The questions below can help you understand the evidence, decide whether another test could answer a specific clinical question, and compare approved treatments, off-label options and clinical trials.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Oncologic Critical Care | $1,110.00 | Buy on Amazon |
| 2 |
|
DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Print + eBook with... | $344.47 | Buy on Amazon |
| 3 |
|
Wintrobe's Clinical Hematology: Print + eBook with Multimedia | $396.66 | Buy on Amazon |
| 4 |
|
Geriatric Oncology (Springer Reference) | $1,044.19 | Buy on Amazon |
| 5 |
|
Encyclopedia of Cancer | $1,744.71 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
What targeted therapy is—and why a match may not last
Targeted therapies are medicines designed to interfere with proteins or other cancer features that help malignant cells grow, divide or spread. Before many of these drugs are selected, a tumor is tested for a biomarker or molecular alteration that might make the cancer vulnerable. The National Cancer Institute (NCI) explains the basic approach in Targeted Therapy to Treat Cancer.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesA biomarker match increases the rationale for using a drug; it does not guarantee that every cancer cell carries the same vulnerability or that the response will continue indefinitely. Tumors contain populations of cells with different characteristics. Treatment can suppress sensitive cells while leaving a minority that can survive and expand.
#1 Best Overall
“Cancer cells can become resistant to targeted therapy,” NCI states. Resistance therefore describes a change in the cancer’s response, not a failure by the patient to take the medicine correctly. Your oncology team still needs to check adherence, dosing, interactions and other clinical factors, but resistance is a biological property of the tumor that requires evidence-based evaluation.
Intrinsic and acquired resistance
Intrinsic resistance: present before treatment
Intrinsic (or primary) resistance means that resistant cells or molecular features already existed when treatment began. The tumor may contain a small group that does not depend on the drug’s target, or whose target is altered enough that the medicine has little effect. Sensitive cells can shrink while that resistant group remains and later becomes the dominant population.
Acquired resistance: emerging during treatment
Acquired (or secondary) resistance develops after treatment has applied selective pressure. Cells that survive can accumulate or select changes that let them resume growth despite the drug. NCI’s overview, Why Do Cancer Treatments Stop Working? Overcoming Treatment Resistance, describes resistance as a process that can involve the drug target, the way the drug interacts with the tumor, broader changes inside cancer cells and the tumor microenvironment.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallRank #2
These categories are useful for explaining timing, but they are not mutually exclusive in a practical sense. A tumor can begin with one resistant population and acquire additional changes later. Different metastases in the same person can also behave differently, so a test from one site may not represent every cancer cell in the body.
How cancer can evade a targeted drug
The target changes
A genetic or other molecular alteration can change the protein a drug is meant to block. The medicine may bind less effectively, or the cancer may produce enough altered target to continue signaling. In this situation, the original biomarker may still be detectable while the drug-target interaction has changed.
A bypass pathway takes over
Cancer cells can activate a different protein or signaling route that supplies the same growth or survival instruction. The original target may remain inhibited, yet the cell no longer depends on that pathway. This is why resistance is not always explained by a new mutation in the original target.
Cell-wide and microenvironment changes
Changes in gene regulation, cell state, drug transport, DNA repair or interactions with surrounding stromal and immune cells can alter sensitivity without a single obvious target mutation. NCI notes that more than one mechanism can operate in the same tumor, which makes a universal resistance test or treatment impossible.
Genetic diversity and extrachromosomal DNA
In a March 17, 2023 NCI report on melanoma research, investigators examined extrachromosomal DNA and complex genomic rearrangements as ways cancer cells may generate genetic changes associated with resistance. UCLA’s Roger Lo, M.D., Ph.D., said, “Inevitably, cancer cells capable of generating many versions of themselves will chance upon certain genetic variants that are able to resist a therapy.” The report described a proposed strategy and a clinical trial being developed to test it; it was not presented as established treatment for every melanoma or for other cancers. Read the report at Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies.
How clinicians determine whether a treatment is failing
A scan that looks different is not automatically proof of resistance. Your team may compare imaging over time, perform a physical examination, review symptoms and laboratory results, and consider whether inflammation, infection, treatment effects or measurement uncertainty could explain a change. NCI describes regular visits, examinations, blood tests and imaging as parts of monitoring treatment response in its targeted-therapy information.
Rank #4
Ask what specific evidence shows that the cancer is growing or that the current treatment is no longer controlling it. Clarify whether the concern is progression at one site, progression in several sites, a new lesion, a biomarker result or a side effect that requires a different dose. The distinction matters because the next step may be confirmation, continued observation, a dose change or a new treatment—not automatically a different drug.
Could another biomarker test help?
NCI’s Biomarker Testing for Cancer Treatment explains that genomic and other biomarker tests can inform treatment selection and identify possible clinical trials. Whether repeat testing is useful depends on the cancer type, the treatment already given, the site that is changing and the clinical question your oncologist is trying to answer. A consumer genetic test is not a substitute for a clinically indicated tumor test.
Tissue biopsy
A tissue biopsy removes a sample from a tumor or metastasis for laboratory analysis. It can provide information about the cells’ morphology and a broad range of biomarkers, depending on the specimen and assay. Ask which lesion would be sampled, whether it is safely accessible, what procedure and recovery involve, when results are expected and what risks—such as bleeding, infection, pain or injury to nearby structures—apply in your situation.
Best Value
Blood-based liquid biopsy
A liquid biopsy analyzes cancer-derived material, such as circulating tumor DNA, in blood or another body fluid. It may identify a molecular alteration without an invasive procedure, but a negative result can mean that the test did not detect enough tumor material rather than that no alteration exists. It may not show the architecture, protein expression or microenvironment information available from tissue. NCI emphasizes that the usefulness of a particular liquid biopsy is a clinical question.
| Question | Tissue sample | Blood-based liquid biopsy |
|---|---|---|
| What it can examine | Cells and selected molecular biomarkers in the sampled lesion; the exact scope depends on the assay and specimen quality. | Biomarkers released into blood or another fluid; detection depends on how much tumor material enters the sample. |
| How it is obtained | A procedure to remove tissue from a chosen tumor site. | A blood draw or collection of another body fluid. |
| Potential limitations | Invasive risks and the possibility that one sampled site does not represent all disease. | A negative result may be uninformative when little tumor DNA is circulating; it cannot answer every tissue-level question. |
| Decision it might change | Whether a resistance alteration or other biomarker is present and which treatments or trials merit discussion. | Whether a detectable alteration supports a treatment or trial discussion, or whether tissue testing is still needed. |
These are general distinctions, not a ranking. Your oncologist should explain which test is analytically valid, available, covered or affordable, and capable of changing a decision in your case. NCI’s Research Areas: Cancer Diagnosis provides additional context on diagnostic research.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Questions to take to your oncology appointment
NCI recommends preparing questions and bringing a written list to appointments; its patient checklist is available at Questions to Ask Your Doctor about Cancer. You can select only the prompts that fit your situation.
Establish what is happening
- “What evidence shows that my cancer is growing or that this treatment is no longer controlling it?”
- “Is the change definite, or do we need another scan, examination or interval of monitoring to confirm it?”
- “Is the concern limited to one tumor site, or are several sites changing?”
Ask about the biology
- “Could a change in the tumor’s biomarkers help explain what is happening?”
- “Does the pattern suggest a changed drug target, a bypass pathway or another mechanism?”
- “Could different metastases have different resistance mechanisms?”
Decide whether testing is worthwhile
- “Would another tumor test be useful now, and what decision would its result change?”
- “What would a tissue biopsy involve in my case, and what are its specific risks?”
- “Could a blood-based liquid biopsy answer a useful question for me, and what would it not tell us?”
- “If the test is negative or inconclusive, what would we do next?”
- “How long would results take, and could treatment continue while we wait?”
Compare treatment paths
- “Are there approved options, off-label options or clinical trials that fit my cancer and test results?”
- “What benefits, side effects and uncertainties should I weigh for each option?”
- “Would a combination or sequence of treatments be supported by evidence for my cancer, or is it experimental?”
- “What practical requirements apply—additional visits, monitoring, travel, eligibility tests or costs?”
Plan monitoring
- “How will we monitor whether the next treatment is working?”
- “Which symptoms or test results should prompt me to contact the team?”
- “When will we reassess, and what would count as a response, stable disease or progression?”
How to compare an approved treatment, off-label use and a clinical trial
“Approved” means the relevant regulator has authorized the medicine for a specified use; the indication may not match every cancer type or resistance pattern. “Off-label” means a clinician is using an approved medicine in a way that is not the labeled indication. A clinical trial follows a research protocol with eligibility rules, defined monitoring and informed consent. None of these labels alone tells you which choice is best.
| Comparison point | Questions for your team |
|---|---|
| Evidence and purpose | What is known for my tumor type, biomarker and prior treatment? Is the goal tumor shrinkage, disease control, symptom relief or learning whether a strategy is safe? |
| Expected benefit | What outcomes have been observed, over what time frame, and how uncertain is that estimate for someone like me? |
| Harms and burden | Which side effects are common or serious? What monitoring, procedures, travel or time away from work and family are required? |
| Eligibility and access | Do my laboratory values, prior therapies, organ function and other factors meet the requirements? What happens if I do not qualify? |
| Next decision | What result would make us continue, stop, switch or add another treatment? |
Resistance strategies—including combinations intended to delay or overcome resistance—are an active area of research. Their applicability must be judged by the oncology team; an approach studied in one cancer, such as the melanoma strategy described in the 2023 NCI report, should not be treated as standard care elsewhere.
Preparing for a useful conversation
- Write down the treatment name, dose schedule, start date, missed doses and new medicines or supplements.
- Bring the dates and reports for recent scans, biopsies and biomarker tests if they are available through your patient portal.
- List new symptoms, when they began, what makes them better or worse and how they affect daily activities.
- Take a support person or ask whether the visit can be recorded under the clinic’s policy, so you can review complex information later.
- Ask the team to define unfamiliar terms—such as progression, mutation, variant, biomarker, liquid biopsy, off-label and trial—and to explain what action each result would trigger.
- Request written instructions for monitoring, side-effect reporting and the date of the next decision point.
These steps do not replace medical advice. They help you and your caregivers understand the evidence behind a change in treatment and make questions specific to your cancer, prior therapy and goals.
Quick Recap
What to remember about resistance
- A targeted-treatment match is a starting point, not a promise of permanent control.
- Resistance can be intrinsic, acquired or a combination of mechanisms, and it is not always caused by a new mutation.
- Repeat tissue or liquid testing may be useful when it can answer a defined question and alter a treatment or trial decision; it is not automatically needed for every patient.
- Ask your oncologist what evidence demonstrates progression, what each proposed test can and cannot show, and how each possible result would change care.
- There is no universal resistance treatment. Approved therapies, off-label options and clinical trials must be weighed against expected benefits, harms, uncertainty and access for your particular cancer.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Recommended Free Tools
